SMAD4 and colorectal carcinoma: Synergistic action of CKD-516 combination and anti-PD-1 mAbs have given promising enough preclinical data for the SMAD-4 deficient MSS-CRC to proceed with the clinical testing of CKD-516/anti-PD1 combination in CRC patients with MSS tumors [107].